Ahsan Alam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11702324/publications.pdf

Version: 2024-02-01

33 papers	966 citations	16 h-index	454955 30 g-index
33 all docs	33 docs citations	33 times ranked	1461 citing authors

#	Article	IF	CITATIONS
1	Multifaceted Intervention to Increase the Use of Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 535-545.	4.5	5
2	Effects of a Knowledge-Translation Intervention on Early Dialysis Initiation: A Cluster Randomized Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 1791-1800.	6.1	3
3	The Impact of COVID-19 on Patients With ADPKD. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110564.	1.1	1
4	Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 32-41.	1.9	4
5	Association Between the Publication of the Initiating Dialysis Early and Late Trial and the Timing of Dialysis Initiation in Canada. JAMA Internal Medicine, 2019, 179, 934.	5.1	13
6	Autosomal dominant polycystic kidney disease. Lancet, The, 2019, 393, 919-935.	13.7	337
7	Health Professional–Identified Barriers to Living Donor Kidney Transplantation: A Qualitative Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811982838.	1.1	22
8	Efficacy of Educational Interventions in Improving Measures of Living-donor Kidney Transplantation Activity: A Systematic Review and Meta-analysis. Transplantation, 2019, 103, 2566-2575.	1.0	10
9	Serial <i>versus</i> single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients. Nephrology, 2018, 23, 69-74.	1.6	9
10	Platelet reactivity in stable cardiovascular patients with chronic kidney disease. Platelets, 2018, 29, 455-462.	2.3	8
11	Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880158.	1.1	27
12	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	1.1	45
13	Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769578.	1.1	28
14	Autosomal Dominant PKD in Patients With PKD2 Mutations–AÂBenign Disorder?. American Journal of Kidney Diseases, 2017, 70, 456-457.	1.9	0
15	Impact of acute kidney injury following liver transplantation on longâ€ŧerm outcomes. Clinical Transplantation, 2017, 31, e12863.	1.6	33
16	Knowledge Translation Interventions to Improve the Timing of Dialysis Initiation. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811666525.	1.1	7
17	Risk factors for progression in ADPKD. Current Opinion in Nephrology and Hypertension, 2015, 24, 290-294.	2.0	4
18	Hepcidin-25 in Diabetic Chronic Kidney Disease Is Predictive for Mortality and Progression to End Stage Renal Disease. PLoS ONE, 2015, 10, e0123072.	2.5	24

#	Article	IF	CITATIONS
19	Total Kidney Volume in Autosomal Dominant Polycystic KidneyÂDisease: A Biomarker of Disease Progression and Therapeutic Efficacy. American Journal of Kidney Diseases, 2015, 66, 564-576.	1.9	51
20	The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrology, 2015, 16, 136.	1.8	18
21	Counterpoint: Statins do reduce fatal events. Journal of Clinical Lipidology, 2013, 7, 225-227.	1.5	O
22	Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients. BMC Nephrology, 2013, 14, 247.	1.8	9
23	Serum Adiponectin Levels and Mortality after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 460-467.	4.5	24
24	Left Ventricular Hypertrophy in ADPKD: Changing Demographics. Current Hypertension Reviews, 2013, 9, 27-31.	0.9	23
25	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology, 2012, 6, 303-309.	1.5	42
26	Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2879-2886.	4.5	21
27	Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1573-1579.	4.5	52
28	Cardiovascular Death in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 335-340.	4.5	40
29	Evaluating cimetidine for GFR estimation in liver transplant recipients. Nephrology Dialysis Transplantation, 2010, 25, 1285-1289.	0.7	4
30	Management of ESRD in Patients With Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 164-172.	1.4	41
31	A Review of Multiple Myeloma Patients on Dialysis Treated with High Cutoff Hemodialysis. Blood, 2010, 116, 5002-5002.	1.4	3
32	Decreased Survival in Liver Transplant Patients Requiring Chronic Dialysis: A Canadian Experience. Transplantation, 2008, 85, 1277-1280.	1.0	57
33	Granulocyte colonyâ€stimulating factor with or without immunosuppression reduction in neutropenic kidney transplant recipients. Clinical Transplantation, 0, , .	1.6	1